Level C· Early human research exploring benefitsProspective StudyPubMed

Effects of 15-lipoxygenase overexpressing adipose tissue mesenchymal stem cells on the Th17 / Treg plasticity.

Özdemir AT., Nalbantsoy A., Özgül Özdemir RB., Berdeli A.

Prospective Study on Immune Modulation, published in Prostaglandins Other Lipid Mediat (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Prostaglandins Other Lipid Mediat (2021)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
34963632
DOI
10.1016/j.prostaglandins.2021.106610

Abstract (original English)

15-lipoxygenase (15-LOX) is a critical enzyme that allows the direction of arachidonic acid metabolism to change from inflammation into the resolution. This study aims to reveal how the immunomodulation properties of mesenchymal stem cells (MSC) alter by the 15-LOX overexpression. For this purpose, peripheral blood mononuclear cells (PBMCs) isolated from seven healthy volunteers, and both MSCs and 15-LOX overexpressing MSCs ( 15-LOX MSCs) were co-cultured at different cell ratios (1/1, 1/5 and 1/10). Alterations of CD4 + Tbet + , CD4 + Gata3 + , CD4 + RoRC2 + , and CD4 + FoxP3 + lymphocyte frequencies were detected by flow cytometry, and IFN-γ, IL-4, IL-6, IL-10, IL-17a, TGF-β and LXA 4 levels of medium supernatants were measured by ELISA method. According to our findings, MSC and 15-LOX MSCs have a suppressive effect on PHA activated PBMCs. However, as the ratio of PBMCs increased, the effects of 15-LOX MSCs increased significantly, while the effects of MSCs decreased. The most notable effect of the 15-LOX modification was the significant reduction in IL-6, IL-10 and IL-17a expression and the accompanying increase in TGF-β and LXA 4 levels. We also observed a similar situation between CD4 + RoRC2 + and CD4 + FoxP3 + cell frequencies. These data suggested that the effects of MSCs on the balance of Th17 / Treg could change by the 15-LOX overexpression, and this might be in favor

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueArachidonate 15-LipoxygenaseForkhead Transcription FactorsHumansInterleukin-10Interleukin-17Interleukin-6Leukocytes, MononuclearMesenchymal Stem CellsT-Lymphocytes, Regulatory

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research